AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $213.72M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.08M
Average 0.32M
ACIU Net Income
Bottom-line profit after all expenses, interest, and taxes.
AC Immune S.A.NASDAQ: ACIU
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -CHF 14.8M, compared with -CHF 19.03M a year earlier. Trailing-twelve-month net income was -CHF 66.22M.
Context
- Net income amounted to 1971.6% of revenue in FY2025, up 1785.2 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -CHF 40.1M (+43.1%) for the fiscal year ending Dec 2026, a step up from the -38.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CHF 14.8M-3.0% QoQ
- Last fiscal yearDec 2025
- -CHF 70.45M-38.4% YoY
- LTMMar 2026
- -CHF 66.22M-27.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +22.2% | +145.8% | +123.6 pp |
| 1 year | -38.4% | +43.1% | +81.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CHF · from the income statement
- Latest · FY2025
- (70.45M) CHF
- Year-over-year change
- -38.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (70.45M) | -38.4% |
| FY2024 | 2024-12-31 | (50.92M) | +6.1% |
| FY2023 | 2023-12-31 | (54.23M) | +23.3% |
| FY2022 | 2022-12-31 | (70.75M) | +3.1% |
| FY2021 | 2021-12-31 | (73M) | — |
Net Income vs competitors
How ACIU compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.1% is the 9th highest of 10, against a peer median of -11.2%.
- Net income amounts to 1788.8% of revenue for ACIU, versus a peer median of 7139.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$27.37M USD | +52.6% | — | — | |
| LTM Mar 2026 | -$33.61M USD | +61.8% | — | 15.6% | |
| LTM Mar 2026 | -$35.7M USD | +24.2% | — | 7139.7% | |
| LTM Mar 2026 | -$56.88M USD | -75.2% | — | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$58.44M USD | -17.3% | — | — |
| LTM Mar 2026 | -CHF 66.22M CHF | -27.1% | — | 1788.8% | |
| LTM Mar 2026 | -$67.29M USD | -11.2% | — | 98.8% | |
| LTM Mar 2026 | -$74.31M USD | -17.6% | — | — | |
| LTM Mar 2026 | -$85.17M USD | — | — | 9243.0% | |
| LTM Mar 2026 | -$196.48M USD | -17.4% | — | — | |
| LTM Mar 2026 | -$246.41M USD | +26.3% | — | 794858.1% | |
| Peer median (excluding ACIU) | — | -11.2% | — | 7139.7% | |
Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.94M | 14.8M | 27.31M | 3.57M |
| Cost of Revenue | 0 | 0 | 54.61M | 62.57M | 0 |
| Gross Profit | 0 | 3.94M | (39.81M) | (35.26M) | 3.57M |
| Gross Margin | — | 100.0% | -268.9% | -129.1% | 100.0% |
| Research & Development | 62.28M | 60.34M | 54.61M | 62.57M | 56.44M |
| Selling, General & Admin | 10.88M | 9.58M | 10.58M | 11.43M | 11.65M |
| Operating Expenses | 79.01M | 74.78M | 13.82M | 17.12M | 72.44M |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.5M |
| EBITDA | (70.01M) | (68.03M) | (51.83M) | (48.62M) | (67.75M) |
| EBITDA Margin | — | -1728.7% | -350.2% | -178.0% | -1896.2% |
| Operating Income | (79.01M) | (70.85M) | (53.62M) | (52.38M) | (68.86M) |
| Operating Margin | — | -1800.4% | -362.3% | -191.8% | -1927.3% |
| Interest Income | 6.49M | 69K | 1.04M | 3.2M | 1.87M |
| Interest Expense | 581K | 355K | 176K | 133K | 191K |
| Other Income / Expenses | 6.02M | 107K | (599K) | 1.47M | (1.58M) |
| Income Before Tax | (72.99M) | (70.74M) | (54.22M) | (50.91M) | (70.45M) |
| Pre-Tax Margin | — | -1797.7% | -366.3% | -186.4% | -1971.6% |
| Income Tax Expense | 3K | 13K | 10K | 3K | 0 |
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (70.45M) |
| Net Margin | — | -1798.0% | -366.4% | -186.4% | -1971.6% |
| EPS (Basic) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| EPS (Diluted) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| Weighted Avg Shares | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
| Weighted Avg Shares (Diluted) | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.